TCM
ALLO icon

Tekla Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Tekla Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-48,089
Closed -$1.21M – 199
2020
Q4 		$1.21M Buy
+48,089
New +$1.57M 0.04% 173
2020
Q3 		– Sell
-216,069
Closed -$9.25M – 205
2020
Q2 		$9.25M Sell
216,069
-28,192
-12% -$1.02M 0.35% 58
2020
Q1 		$4.75M Buy
244,261
+163,981
+204% +$3.91M 0.21% 87
2019
Q4 		$2.09M Buy
+80,280
New +$2.21M 0.08% 151

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Tekla Capital Management's ALLO Position: Q1 2021 in Review

Tekla Capital Management sold out of Allogene Therapeutics (ALLO) in Q1 2021, closing a stake of 48,089 shares — an estimated $1.21M sold.

Tekla Capital Management first reported a position in ALLO in Q4 2019 and held it in 4 quarters. The position peaked at $9.25M in Q2 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q1 2021.

  • Tekla Capital Management reported no remaining Allogene Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tekla Capital Management sold 48,089 Allogene Therapeutics shares in Q1 2021, an estimated $1.21M.
  • Tekla Capital Management first reported a position in Allogene Therapeutics in Q4 2019 and held it in 4 quarters.
  • Tekla Capital Management's Allogene Therapeutics position peaked at $9.25M in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.